Latest Antiretroviral drug Stories
ORLANDO, Fla., Jan. 5, 2015 /PRNewswire/ -- Immune Therapeutics Inc.
JOHANNESBURG and PITTSBURGH, Dec. 31, 2014 /PRNewswire/ -- Mylan Inc.
CORK, Ireland, December 29, 2014 /PRNewswire/ -- -- Two Companies to also Collaborate on the Further Development of Complera(R), Marketed
Quantitative Test for Rapid Measurement of the HIV-1 Viral Load in Plasma Delivers Individual Results in About 90 Minutes SUNNYVALE, Calif. and GENEVA, Dec.
Using modified human stem cells, a team of UC Davis scientists has developed an improved gene therapy strategy that in animal models shows promise as a functional cure for the human immunodeficiency
- In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than 2 percent of patients experiencing virological failure NORTH CHICAGO, Ill., Dec.
LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S.
PITTSBURGH and LONDON, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S.
The ability of HIV to cause AIDS is weakening, and the virus is becoming less deadly and less infectious as it adapts to our immune systems, according to new research published Monday in the journal Proceedings of the National Academy of Sciences.
Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...
- A person in a secondary role, specifically the second most important character (after the protagonist).